Daiichi Sankyo Company has announced that it has launched the antitumor agent bevacizumab BS for intravenous drip infusions 100 mg and 400 mg “Daiichi Sankyo” (generic name: bevacizumab (genetical recombination) [bevacizumab biosimilar 2], in Japan.

The product is a pharmaceutical agent developed by Amgen Inc. as a biosimilar product to the anti-VEGF humanized monoclonal antibody, bevacizumab. The product was approved on September 20, 2019, and indicated for unresectable advanced or recurrent colorectal cancer.

Based on the exclusive agreement on the commercialization of biosimilars concluded with Amgen in July 2016, Daiichi Sankyo is responsible for the distribution and commercialization of the product in Japan, while Amgen is responsible for its manufacture.

Daiichi Sankyo expects that the product will provide patients with various options for cancer treatment, thereby further contributing to medical treatment in japan.